Pantaleón BOS

Language: Spanish
References: 12
Page:
PDF size: 66.13 Kb.

ABSTRACT

Venous thromboembolic disease combines several fundamental aspects like its frequency and its potential severity in terms of mortality, relapse and postrombotic sequelae. The above mentioned can be reduced through an adequate, effective treatment with anticoagulation for a suitable period of time. With the objective of updating the management and control of oral anticoagulants in the long-term treatment of the deep venous thrombosis, a review was made by using the available databases in Infomed, Medline and articles published in high impact journals in the last 10 years. It was concluded that, after initial heparin treatment, the oral anticoagulants are the treatment of choice to extend anticoagulation and to reach effective protection. It should be added that the emergence of new anticoagulants represents an important advance in the therapeutic arsenal for the prevention of the illness, and brings new alternatives for the long-term treatment.

REFERENCES

1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452-63.

2. Botella G. Reflexiones sobre la enfermedad tromboembólica venosa. An Med Interna. 2003;20:447-50.

3. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-9.

4. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease. Chest. 2008;133;454S-5S.

5. Ost D, Tepper J, Mihara H. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005;294:706-15.

6. Lecumberri R, Feliu J, Rocha E. Nuevas estrategias en la prevención secundaria de la recurrencia de la tromboembolia venosa. Med Clin (Barc). 2005;125:748-55.

7. Cushman M, Folsom AR, Wang L, Aleksic N, Rosamond WD, Tracy RP, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood. 2003;101:1243-8.

8. Páramo JA, Ruiz de Gaona E, García R, Rodríguez P, Lecumberri R. Diagnóstico y tratamiento de la trombosis venosa profunda. Rev Med Univ Navarra. 2007;51:13-7.

9. Heit JA, Lahr BD, Petterson TM, Bailey KR, Ashrani AA, Melton LJ. Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood. 2011;118:4992-9.

10. Vargas AG, Ramírez AN, Medina ME. Nuevos anticoagulantes: Dabigatrán, Rivaroxabán y Apixabán. Gaceta Médica Méx. 2012;148:257-64.

11. Arcelus JI, Cairols M, Granero X, Jiménez D, Llau JV, Monreal M. Conferencia de consenso. Nuevos anticoagulantes orales: una visión multidisciplinaria. Med Clin (Barc). 2009;133:50812.

12. Prins MH, Hutten BA, Koopman MMW, Buller HR. Long-term treatment of venous thromboembolic disease. Thromb Haemost. 1999; 82:892-8.